Brief: Cyclerion Therapeutics Provides Additional Positive CY6463 Melas Clinical Data At A Webinar Hosted By United Mitochondrial Disease Foundation

Korsana Biosciences

28/06/2022 14:58

June 28 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS PROVIDES ADDITIONAL POSITIVE CY6463
MELAS
CLINICAL DATA AT A WEBINAR HOSTED BY UNITED MITOCHONDRIAL
DISEASE FOUNDATION
    * CYCLERION THERAPEUTICS INC - DATA FROM 8-PARTICIPANT,
OPEN-LABEL
STUDY DEMONSTRATE CY6463 WAS WELL TOLERATED
    * CYCLERION THERAPEUTICS - DATA FROM CY6463 STUDY SHOW NO
REPORTS
OF SERIOUS ADVERSE EVENTS (SAES) OR TREATMENT DISCONTINUATION
DUE TO ADVERSE EVENTS

Source text for Eikon:  ID:nGNX853rF 
Further company coverage:  CYCN.O